Biopharmaceutical
-
FDA to streamline biosimilar development to lower drug prices
New federal guidance recommends using drugs approved outside of the US as comparators to cut down on pricey pharmacokinetic testing.
-
FDA launches program to bolster domestic drug manufacturing
The PreCheck program aims to make it significantly less onerous to set up domestic manufacturing plants provided they align with US national priorities.